FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

🆕in JMCC: FABP4 emerges as a marker of worse CVD prognosis🫀 Elevated FABP4 drives proinflammatory, proatherogenic neutrophil phenotypes, while semaglutide lowers FABP4 & dampens leukocyte migration & platelet activation pathways 💊 #JMCC #Atherogenisis

www.jmcc-online.com/article/S002...